108 related articles for article (PubMed ID: 7482688)
1. Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring.
el Battah A; Beglia S; Alric R
Ther Drug Monit; 1995 Aug; 17(4):348-55. PubMed ID: 7482688
[TBL] [Abstract][Full Text] [Related]
2. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
3. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
5. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.
Yukawa E; Aoyama T
J Clin Pharmacol; 1996 Aug; 36(8):752-9. PubMed ID: 8877681
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.
Eriksson AS; Hoppu K; Nergårdh A; Boreus L
Epilepsia; 1996 Aug; 37(8):769-73. PubMed ID: 8764817
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
8. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
9. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
J Clin Pharmacol; 1997 Dec; 37(12):1160-7. PubMed ID: 9506012
[TBL] [Abstract][Full Text] [Related]
10. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
Yukawa E
Drug Metabol Drug Interact; 2000; 16(2):86-98. PubMed ID: 10962642
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
12. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
13. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
Vučićević K; Jovanović M; Golubović B; Kovačević SV; Miljković B; Martinović Ž; Prostran M
Eur J Clin Pharmacol; 2015 Feb; 71(2):183-90. PubMed ID: 25380628
[TBL] [Abstract][Full Text] [Related]
15. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
16. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data.
Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E
Epilepsia; 2003 Jul; 44(7):923-9. PubMed ID: 12823575
[TBL] [Abstract][Full Text] [Related]
17. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
Messina S; Battino D; Croci D; Mamoli D; Ratti S; Perucca E
Epilepsia; 2005 Mar; 46(3):372-7. PubMed ID: 15730534
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
